Randomized, Open-Label, Phase 2/3 Study Of Daratumumab (Dara) With Or Without Jnj-63723283, An Anti-Pd-1 Monoclonal Antibody, In Relapsed/Refractory Multiple Myeloma (Rrmm).
JOURNAL OF CLINICAL ONCOLOGY(2018)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要